Skip to main content
Retour
Watch Compare

Kalaris Therapeutics, Inc.

Qualité des données : 83%
KLRS
Nasdaq Manufacturing Chemicals
5,99 €
▼ 0,35 € (-5,52%)
Cap. Boursière: 137,34 M
Prix
5,99 €
Cap. Boursière
137,34 M
Fourchette du Jour
5,83 € — 6,64 €
Fourchette 52 Semaines
2,14 € — 11,88 €
Volume
60 393
Ouverture 6,40 €
Moyenne 50J / 200J
8,65 €
30,76% below
Moyenne 50J / 200J
6,00 €
0,20% below

Quick Summary

Points Clés

Negative free cash flow of -38,57 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-91,47%
En dessous de la moyenne du secteur (-53,41%)
ROIC-45,49%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio12,89
Interest Coverage-31,98

Valorisation

PE (TTM)
-3,16
En dessous de la moyenne du secteur (-1,48)
P/B Ratio3,28
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -3,2 -1,5
P/B 3,3 1,6
ROE % -91,5 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -43,44 M
ROE -91,47% ROA -49,92%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -38,57 M
ROIC -45,49% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 12,89
Interest Coverage -31,98 Asset Turnover N/A
Working Capital 72,12 M Tangible Book Value 41,87 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,16 Forward P/E N/A
P/B Ratio 3,28 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -28,08%
Market Cap 137,34 M Enterprise Value 94,95 M
Per Share
EPS (Diluted TTM) -2,85 Revenue / Share N/A
FCF / Share -1,68 OCF / Share -1,67
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 88,79%
SBC-Adj. FCF -45,12 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -43,44 M -58,77 M -190,42 M -168,71 M -171,96 M
EPS (Diluted) -2,85 -11,73 -1,83 -2,20 —
Gross Profit — — — — —
Operating Income -46,15 M -65,44 M -199,90 M -171,20 M -169,82 M
EBITDA — — — — —
R&D Expenses 30,75 M 12,34 M 133,07 M 118,87 M 120,74 M
SG&A Expenses — — — — —
D&A — 398 000,0 398 000,0 723 000,0 189 000,0
Interest Expense 1,44 M — — — —
Income Tax 0,0 0,0 -126 000,0 -265 000,0 1,01 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 121,74 M 118,55 M 190,80 M 277,08 M 286,59 M
Total Liabilities 42,92 M 5,24 M 45,02 M 52,56 M 61,33 M
Shareholders' Equity 78,81 M 113,31 M 145,78 M 224,52 M 225,27 M
Total Debt — — — — —
Cash & Equivalents 98,05 M 118,29 M 90,12 M 106,09 M 201,66 M
Current Assets 118,81 M 118,55 M 187,64 M 243,05 M 253,35 M
Current Liabilities 9,71 M 5,24 M 28,37 M 24,34 M 37,85 M